Dual functioning microspheres embedded crosslinked gelatin cryogels for therapeutic intervention in osteomyelitis and associated bone loss.
In the present research,we simultaneously addressed the condition of osteomyelitis and osteoporosis by developing a gelatin based chemically cross linked cryogel system embedded with CaCO3 microspheres and ciprofloxacin hydrochloride was incorporated in both the microspheres and the 3D matrix of cryogel. The fabricated cryogel was characterized for the swelling ratio, swelling kinetics, porosity, pore volume, compression strength and in vitro rate of degradation which were found to be dependent on the concentration of gelatin, duration of freezing and number of freeze-thaw cycles. The sustained release of drug was obtained up to 21days after the initial burst, and the concentration was maintained above the MIC for the entire duration of the study. The in vitro antibacterial study in Staphylococcus aureus and Escherichia coli exhibited 33mm, 30mm, 28mm, 27mm and 43mm, 37mm, 37mm, and 36mm zone of inhibition respectively at day 1, 3, 5 and 7. The cell viability, number of cells in the growth phase and alkaline phosphatase levels were found to be significantly higher in rat osteoblasts cultured in cryogel as compared to 2D surface. All these results demonstrate the propitious potential of this microsphere incorporated, ciprofloxacin-loaded, industrially scalable cryogel system for therapeutic intervention in osteoporosis and associated osteomyelitis.
Pharmaceutics Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow 226031, India.
Gitu
G
Pandey
Pharmaceutics Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow 226031, India.
Naresh
N
Mittapelly
Pharmaceutics Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow 226031, India.
Anamika
A
Pant
Pharmaceutics Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow 226031, India.
Shweta
S
Sharma
Microbiology Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow 226031, India.
Pratiksha
P
Singh
Pharmaceutics Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow 226031, India.
Venkatesh Teja
VT
Banala
Endocrinology Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow 226031, India.
Ritu
R
Trivedi
Microbiology Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow 226031, India.
P K
PK
Shukla
Pharmaceutics Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Lucknow 226031, India.
P R
PR
Mishra
D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D002119:Calcium Carbonate / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002939:Ciprofloxacin / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D059985:Cryogels; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D016503:Drug Delivery Systems; D065546:Drug Liberation; D004926:Escherichia coli / Q000187:drug effects; D005780:Gelatin / Q000737:chemistry; D008863:Microspheres; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism; D010019:Osteomyelitis / Q000188:drug therapy*; D010024:Osteoporosis / Q000188:drug therapy*; D016062:Porosity; D051381:Rats; D013211:Staphylococcus aureus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D059985:Cryogels; D003692:Delayed-Action Preparations; D002939:Ciprofloxacin; D005780:Gelatin; D000469:Alkaline Phosphatase; D002119:Calcium Carbonate
Alkaline phosphatase; Bone loss; Calcium carbonate microspheres; Ciprofloxacin; Cryogels; Flow cytometry; Osteomyelitis